JCI Insight (Sep 2022)

A specific upregulated long noncoding RNA in colorectal cancer promotes cancer progression

  • Junshu Li,
  • Yanhong Ji,
  • Na Chen,
  • Huiling Wang,
  • Chao Fang,
  • Xiaonan Yin,
  • Zhiyuan Jiang,
  • Zhexu Dong,
  • Dan Zhu,
  • Jiamei Fu,
  • Wencheng Zhou,
  • Ruiyi Jiang,
  • Ling He,
  • Zhang Hantao,
  • Gang Shi,
  • Lin Cheng,
  • Xiaolan Su,
  • Lei Dai,
  • Hongxin Deng

Journal volume & issue
Vol. 7, no. 15

Abstract

Read online

Long noncoding RNA (lncRNA) plays a crucial role in the pathogenesis of various diseases, including colorectal cancer (CRC). The gene mutations of adenomatous polyposis coli (APC) were found in most patients with CRC. They function as important inducers of tumorigenesis. Based on our microarray results, we identified a specific upregulated lncRNA in CRC (SURC). Further analysis showed that high SURC expression correlated with poorer disease-free survival and overall survival in patients with CRC. Furthermore, we found that mutated APC genes can promote the transcription of SURC by reducing the degradation of β-catenin protein in CRC. Functional assays revealed that knockdown of SURC impaired CRC cell proliferation, colony formation, cell cycle, and tumor growth. Additionally, SURC promotes CCND2 expression by inhibiting the expression of miR–185-5p in CRC cells. In conclusion, we demonstrate that SURC is a specific upregulated lncRNA in CRC and the SURC/miR–185-5p/CCND2 axis may be targetable for CRC diagnosis and therapy.

Keywords